These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 25556152)

  • 21. Management of endocrine disease: GH excess: diagnosis and medical therapy.
    Andersen M
    Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
    Pirker W; Riedl M; Luger A; Czech T; Rössler K; Asenbaum S; Angelberger P; Kornhuber J; Deecke L; Podreka I; Brücke T
    J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly.
    Kasuki L; Wildemberg LE; Gadelha MR
    Eur J Endocrinol; 2018 Mar; 178(3):R89-R100. PubMed ID: 29339530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New medical therapies of acromegaly.
    Maffezzoni F; Frara S; Doga M; Mazziotti G; Giustina A
    Growth Horm IGF Res; 2016; 30-31():58-63. PubMed ID: 27745780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pituitary disorders. Drug treatment options.
    Orrego JJ; Barkan AL
    Drugs; 2000 Jan; 59(1):93-106. PubMed ID: 10718101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
    Teramoto A; Sanno N; Tahara S; Osamura YR
    Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatostatin and somatostatin receptors in Cushing's disease.
    Hofland LJ
    Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
    Rimareix F; Grunenwald S; Vezzosi D; Rivière LD; Bennet A; Caron P
    Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thyrotropin-secreting pituitary adenomas: biological and molecular features, diagnosis and therapy.
    Losa M; Fortunato M; Molteni L; Peretti E; Mortini P
    Minerva Endocrinol; 2008 Dec; 33(4):329-40. PubMed ID: 18923369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multimodality treatment of pituitary adenomas.
    Oyesiku NM
    Clin Neurosurg; 2005; 52():234-42. PubMed ID: 16626076
    [No Abstract]   [Full Text] [Related]  

  • 31. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
    Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
    Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormone secretion by pituitary adenomas is characterized by increased disorderliness and spikiness but more regular pulsing.
    Roelfsema F; Pereira AM; Biermasz NR; Veldhuis JD
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3836-44. PubMed ID: 25014002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological management of secreting pituitary tumors.
    Gordon BM
    J Neurosci Nurs; 2007 Feb; 39(1):52-7. PubMed ID: 17396539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Giant pituitary adenoma: histological types, clinical features and therapeutic approaches.
    Iglesias P; Rodríguez Berrocal V; Díez JJ
    Endocrine; 2018 Sep; 61(3):407-421. PubMed ID: 29909598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
    Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
    Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds.
    Zatelli MC; Ambrosio MR; Bondanelli M; Uberti ECD
    Eur J Endocrinol; 2007 Apr; 156 Suppl 1():S29-S35. PubMed ID: 17413185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pituitary adenomas--where is the treatment heading at the beginning of the 21st century?].
    Marek J
    Vnitr Lek; 2010 Jul; 56(7):690-4. PubMed ID: 20842914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis.
    Mondin A; Manara R; Voltan G; Tizianel I; Denaro L; Ferrari M; Barbot M; Scaroni C; Ceccato F
    Front Endocrinol (Lausanne); 2022; 13():935759. PubMed ID: 35846311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medical management of pituitary adenomas: the special case of management of the pregnant woman.
    Bronstein MD; Salgado LR; de Castro Musolino NR
    Pituitary; 2002; 5(2):99-107. PubMed ID: 12675507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complete Shrinking of Mixed Growth Hormone and Prolactin-Secreting Pituitary Adenoma With Bromocriptine Therapy Alone.
    Fan J; Shen H; Mo J; Zhang J
    J Craniofac Surg; 2024 Oct; 35(7):e620-e622. PubMed ID: 38710062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.